// App-Quantinova.ai

P185 : Long-term efficacy and safety of upadacitinib in patients with psoriatic arthritis refractory to biologic therapies: 2-year results from the phase 3 SELECT-PsA 2 study

Researchers

Presenter

  • Philip J Mease

Principal Investigators

  • Arathi Setty

  • Kim Papp

  • Filip van Den Bosch

  • Shigeyoshi Tsuji

  • Mauro Keiserman

  • Xianwei Bu

  • Liang Chen

  • Reva McCaskill

  • Erin McDearmon-Blondell

  • Peter Wung

  • William Tillett

Medical Centers

  • Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, VIB Center for Inflammation Research, Ghent, Belgium

  • Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Allegology, National Hospital Organization Osaka Minami Medical Center, Osaka, Japan

  • Rheumatology, Pontifical Catholic University, School of Medicine, Porto Alegre, Brazil

  • Dermatology, Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada

Locations

  • Belgium

  • Japan

  • United States

  • Brazil

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved